The WELT communicates with your phone to tell you how many steps you've taken, how long you've been sitting, eating habits and your waistline size. It then sends the data to a specially-designed app for analysis, to tell you things like -- if you keep eating like you did today, you're going to gain 2 pounds this month. Samsung expects the WELT to go on sale this year.If the product becomes a commercial success, it's easy to imagine how much historical data the company is going to collect across a broad range of demographic categories. Even if this particular product flops in the market, similar ones, e.g. made by FitBit or Apple, will emerge over time. The key difference between Samsung and others is that Samsung is now getting into pharmaceuticals. Here's a quote from a 2014 Bloomberg article:
South Korea’s biggest company is investing at least $2 billion in biopharmaceuticals, including the growing segment of biosimilars, which are cheaper versions of brand-name biotechnology drugs that have lost patent protection.
“We are in an infancy still,” Christopher Hansung Ko, chief executive officer at the Samsung Bioepis unit, said in an interview. “We are a Samsung company. Our mandate is to become No. 1 in everything we enter into, so our long-term goal is to become a leading pharmaceutical company in the world.”
Remarkably, Samsung has a chance to become the only company in the world capable of gathering real-time biological data, diagnosing diseases and delivering appropriate treatments to an individual at the right time, in the right place and at the right price.
tags: innovation, samsung, health, detection, tool, mobile